Phase 1 study for people with Prostate Cancer

Recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 13 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 1
Sponsor Genentech, Inc.
Registry number NCT05800665
Started 2 May 2023 Today 16 October 2026 Estimated completion 30 June 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
St Vincent's Hospital Sydney Darlinghurst NSW Recruiting
Macquarie University Hospital New South Wales NSW Recruiting
Monash Health Monash Medical Centre Clayton VIC Recruiting
Austin Hospital Heidelberg VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 13 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Male participants only
Healthy volunteers Not accepted
Enrolment target 210

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.

2. Metastatic prostate adenocarcinoma without small-cell carcinoma or neuroendocrine features.

3. Prior therapy with a second-generation androgen receptor (AR)-targeted therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide).

4. Prior therapy with a taxane regimen or are considered ineligible for treatment with a taxane regimen or have refused treatment with a taxane regimen, unless otherwise specified.

5. For participants with a known pathogenic breast cancer gene 1 (BRCA1) or BRCA2 mutation: prior therapy with a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor, or are considered ineligible for treatment with a PARP inhibitor, if such therapy is approved and available.

Key Exclusion Criteria:

1. Treatment with any approved systemic anti-cancer therapy within 14 days or 5 drug elimination half-lives (whichever is longer, not to exceed 28 days) prior to the first study treatment.

2. Treatment with any investigational agent within 28 days prior to the first study treatment.

3. Treatment with any previous AR protein degrader.

4. Untreated central nervous system (CNS) metastases or leptomeningeal disease.

Note: Other protocol specified inclusion/exclusion criteria may apply.

Dates on the record

Started 2 May 2023
Estimated completion 30 June 2027
Registry last updated 6 October 2026
Checked by Voxsanity 13 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 6 October 2026.
  • This page last checked by Voxsanity: 13 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.